Glenna Mileson - 18 May 2021 Form 4 Insider Report for Athira Pharma, Inc. (ATHA)

Role: Chief Financial Officer
Signature: /s/ Glenna Mileson
Issuer symbol: ATHA
Transactions as of: 18 May 2021
Net transactions value: +$30,967
Form type: 4
Filing time: 10 Jun 2021, 18:48:21 UTC
Next filing: 06 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ATHA	Common Stock	Award	$22,455	+1,554	+1.9%	$14.45^*	83,519	18 May 2021	Direct	F1, F2, F3
transaction	ATHA	Common Stock	Options Exercise	$8,512	+6,305	+7.5%	$1.35	89,824	10 Jun 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ATHA	Stock Option (Right to Buy)	Options Exercise	$0	-6,305	-50%	$0.000000	6,305	10 Jun 2021	Common Stock	6,305	$1.35	Direct	F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reporting person is voluntarily reporting the acquisition of shares of the issuer's common stock pursuant to the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan ("ESPP"), for the ESPP Purchase Period (as defined in the ESPP) of October 2, 2020 through May 18, 2021. This transaction is also exempt under Rule 16b-3(c).
F2	The Purchase Period ended May 18, 2021 and is the Purchase Period comprising the Offering Period (as defined in the ESPP) that began October 2, 2020.
F3	In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the initial public offering price from the issuer's initial public offering.
F4	The shares subject to the option fully vested on January 1, 2021.